#1 Clinical Trials Search in Europe

Bictegravir

Bictegravir is a novel antiretroviral medication being studied in clinical trials for the treatment of HIV-1 infection. As part of a single-tablet regimen combined with emtricitabine and tenofovir alafenamide (B/F/TAF), bictegravir shows promise in providing effective, well-tolerated treatment for diverse populations of people living with HIV. This article summarizes key findings from recent clinical trials evaluating bictegravir-based regimens.

Table of Contents

What is Bictegravir?

Bictegravir is a medication used to treat HIV-1 infection in adults. It belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs), which work by blocking an enzyme that HIV needs to multiply[1]. Bictegravir is often referred to by its brand name Biktarvy, which is a combination pill that includes two other HIV medications: emtricitabine and tenofovir alafenamide[2].

How Bictegravir Works

Bictegravir works by preventing HIV from inserting its genetic material into human cells. This stops the virus from making copies of itself and spreading throughout the body. By doing this, bictegravir helps to lower the amount of HIV in the blood (known as viral load) and increase the number of CD4 cells, which are important immune cells that help fight infections[1].

Conditions Treated with Bictegravir

Bictegravir is primarily used to treat HIV-1 infection in adults. It can be used in different situations:

  • For people who are starting HIV treatment for the first time (treatment-naive)[1]
  • For people who are already on HIV treatment but want to switch to a new regimen (treatment-experienced)[2]
  • In people with advanced HIV disease (low CD4 count or AIDS-defining illnesses)[3]
  • For HIV prevention after potential exposure to the virus (post-exposure prophylaxis or PEP)[4]

Bictegravir Formulations

Bictegravir is most commonly available as part of a combination pill called Biktarvy. This single tablet contains:

  • Bictegravir 50 mg
  • Emtricitabine 200 mg
  • Tenofovir alafenamide 25 mg

This combination allows patients to take just one pill once a day, which can make it easier to stick to the treatment regimen[2].

Effectiveness of Bictegravir

Clinical trials have shown that bictegravir-based regimens are highly effective in treating HIV. Some key findings include:

  • High rates of viral suppression (HIV RNA less than 50 copies/mL) at 24 and 48 weeks of treatment[1]
  • Effectiveness in both treatment-naive and treatment-experienced patients[2]
  • Potential for rapid start of treatment in newly diagnosed patients, including those with advanced HIV[3]

Safety and Side Effects

Bictegravir is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea
  • Headache
  • Fatigue
  • Abnormal dreams

Most side effects are mild and tend to improve over time. Serious side effects are rare but can occur. Your healthcare provider will monitor you for any potential issues[1][4].

Use in Special Populations

Bictegravir has been studied in various populations, including:

  • People with kidney problems: Bictegravir/emtricitabine/tenofovir alafenamide may be safer for the kidneys compared to older HIV medications[5]
  • People who use illicit substances: Studies are ongoing to evaluate the effectiveness of bictegravir in this population[6]
  • Marginalized populations: Research is being conducted to assess the benefits of switching to bictegravir-based regimens in underserved communities[7]

Drug Interactions

Bictegravir has fewer drug interactions compared to some older HIV medications. However, it’s important to tell your healthcare provider about all medications, supplements, and herbal products you use. Some medications that may interact with bictegravir include:

  • Certain medications for tuberculosis
  • Some seizure medications
  • Antacids and iron supplements (these should be taken at different times than bictegravir)

Switching to a bictegravir-based regimen may reduce the number of drug interactions for some patients[8].

Ongoing Research

Research on bictegravir is ongoing, with studies looking at:

  • Long-term effectiveness and safety
  • Use in specific populations, such as people who use illicit substances
  • Impact on quality of life and sleep
  • Effects on the gut microbiome

These studies will help to further understand the benefits and potential risks of bictegravir-based HIV treatment[9].

Aspect Details
Drug Formulation Single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF)
Populations Studied Treatment-naive and experienced adults, patients with renal impairment, active substance users, Hispanic/Latinx patients with advanced HIV
Key Efficacy Measures Viral suppression (HIV RNA <50 copies/mL), CD4 cell recovery, time to viral suppression
Safety Assessments Adverse events, laboratory abnormalities, renal function changes
Potential Advantages High barrier to resistance, few drug-drug interactions, efficacy in some pre-existing resistance, single-tablet convenience
Special Populations Studies in patients with renal impairment, active substance use, and advanced HIV
Comparative Studies Evaluations against other antiretroviral regimens, including multi-tablet regimens

FAQ

  • What is bictegravir and how does it work? Bictegravir is an integrase strand transfer inhibitor (INSTI) that blocks the HIV virus from integrating its genetic material into human cells. It is part of a single-tablet regimen combined with emtricitabine and tenofovir alafenamide (B/F/TAF) for treating HIV-1 infection.
  • What populations have been studied in bictegravir clinical trials? Clinical trials have evaluated bictegravir in diverse populations including treatment-naive and treatment-experienced adults, people with renal impairment, those with active substance use, and Hispanic/Latinx patients with advanced HIV.
  • What are some key efficacy outcomes for bictegravir in clinical trials? Clinical trials have shown high rates of viral suppression (HIV RNA <50 copies/mL) in patients taking bictegravir-based regimens, including in treatment-naive patients and those switching from other regimens. Studies are evaluating time to viral suppression and CD4 cell recovery.
  • How is the safety and tolerability of bictegravir being assessed? Safety assessments include monitoring for adverse events, laboratory abnormalities, and changes in renal function. Tolerability is evaluated through measures like treatment discontinuation rates and quality of life questionnaires.
  • What are some potential advantages of bictegravir-based regimens? Potential advantages being studied include a high barrier to resistance, few drug-drug interactions, efficacy in patients with some pre-existing resistance, and the convenience of a single-tablet regimen. Studies are evaluating outcomes in patients switching from multi-tablet regimens.

Ongoing Clinical Trials on Bictegravir

  • Study of Bictegravir and Lenacapavir for Children and Adolescents with HIV-1

    Recruiting

    4 1 1 1
    Investigated drugs:
    Italy Spain

  • Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

  • Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

    Not yet recruiting

    4 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain Sweden

  • Study on Switching HIV Treatment to Doravirine and Islatravir for Patients with HIV-1

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

    Not recruiting

    4 1 1 1
    Investigated drugs:
    Germany Poland Portugal Romania Spain

  • Study to Compare Weekly Islatravir/Lenacapavir with Bictegravir/Emtricitabine/Tenofovir in People with HIV-1 Who Are Virologically Suppressed

    Not recruiting

    3 1 1
    Investigated drugs:
    France Germany Spain

  • Study Comparing DTG/3TC and BIC/FTC/TAF for Maintaining HIV Control in Adults

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Switching to Emtricitabine, Tenofovir Alafenamide, and Bictegravir for HIV-1 Patients Unable or Unwilling to Continue Injectable Therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Effects of Doravirine on Liver Health in People Living with HIV with Liver Steatosis or Fibrosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

    Not recruiting

    3 1 1
    Investigated drugs:
    France Germany Spain

Glossary

  • Antiretroviral therapy (ART): Medications used to treat HIV infection by suppressing viral replication and preventing disease progression.
  • Viral suppression: When antiretroviral therapy reduces a person's viral load to an undetectable level (usually defined as <50 copies/mL).
  • CD4 count: A measure of immune system health in people with HIV; higher numbers indicate a stronger immune system.
  • Integrase strand transfer inhibitor (INSTI): A class of antiretroviral drugs that block the HIV enzyme integrase, preventing the virus from inserting its genetic material into human cells.
  • Drug-drug interaction: When one medication affects the activity of another medication when taken together, potentially impacting effectiveness or side effects.
  • Pharmacokinetics: The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion.
  • Treatment-naive: Patients who have never taken antiretroviral therapy before.
  • Treatment-experienced: Patients who have previously taken antiretroviral therapy.
  • Single-tablet regimen: A complete antiretroviral treatment regimen combined into one pill taken once daily.
  • Viral blip: A temporary, detectable increase in HIV viral load (usually between 50-1000 copies/mL) in a person who was previously virally suppressed.

References

  1. https://clinicaltrials.gov/study/NCT02275065
  2. https://clinicaltrials.gov/study/NCT03502005
  3. https://clinicaltrials.gov/study/NCT05526118
  4. https://clinicaltrials.gov/study/NCT03499483
  5. https://clinicaltrials.gov/study/NCT02400307
  6. https://clinicaltrials.gov/study/NCT03998176
  7. https://clinicaltrials.gov/study/NCT04132674
  8. https://clinicaltrials.gov/study/NCT03789968
  9. https://clinicaltrials.gov/study/NCT04805944